The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

Villines, Todd C.; Stanek, Eric J.; Devine, Patrick J.; Turco, Mark; Miller, Michael; Weissman, Neil J.; Griffen, Len; Taylor, Allen J.

doi:10.1016/j.jacc.2010.03.017

Cited by 207 publications

(135 citation statements)

References 14 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…Ускорение АТ в ответ на ристомицин у больных обусловлено усилением выработки в эндотелии сосу-дов фактора Виллебранда [15]. Короткая длитель-ность АТ с сочетаниями индукторов и большое число агрегатов тромбоцитов в крови пациентов до и после венозной окклюзии указывали на выраженное осла-бление сосудистого контроля над активностью тром-боцитов у пациентов в условиях, близких к реальным.…”

Section: Discussionunclassified

Aggregation Properties of Blood Cells and Vascular Control Over Them in Patients With Arterial Hypertension and Dyslipidemia

Медведев¹,

Скорятина²

2015

Ross. kardiol. ž.

View full text Add to dashboard Cite

Цель. Установить выраженность агрегации клеток крови и особенности анти-агрегационного контроля сосудов у лиц с артериальной гипертонией и дисли-пидемией. Материал и методы. Работа проведена на 380 больных артериальной гипер-тонией 1-2 степени, риск 4 с дислипидемией IIб типа, среднего возраста. Контроль представлен 26 здоровыми людьми аналогичного возраста. Иссле-дования велись с применением биохимических, гематологических и статисти-ческих методов исследования. Результаты. У обследованных пациентов с артериальной гипертонией и дислипидемией отмечено ослабление антиоксидантной защиты плазмы с активацией в ней процессов перекисного окисления липидов, в значитель-ной мере стимулирующих форменные элементы крови и вызывающих альте-рацию сосудистой стенки. У наблюдаемых лиц обнаружено выраженное уси-ление агрегации эритроцитов, тромбоцитов и нейтрофилов. При этом у боль-ных установлено ослабление контроля со стороны сосудистой стенки над возросшей агрегационной способностью форменных элементов крови. заключение. При сочетании артериальной гипертонии с дислипидемией отмечается избыточная агрегация эритроцитов, тромбоцитов и нейтрофилов при ослаблении дезагрегирующего контроля над нею со стороны сосудистой стенки. Российский кардиологический журнал AGGREGATION PROPERTIES OF bLOOD CELLS AND VASCULAR CONTROL OVER THEM IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIAMedvedev I. N., Skoryatina I. A.Aim. To find out the strength of blood cells aggregation properties and specifics of antiaggregation vascular control in persons with arterial hypertension and dyslipidemia. Material and methods. The study was done on 380 patients with arterial hypertension of 1-2 grade, risk 4 with dyslipidemia IIb type, of middle age. Controls were 26 healthy same aged people. Studies were done with biochemical, hematological and statistical methods. Results. Among the patients studied with arterial hypertension and dyslipidemia we found a decrease of antioxidant plasma protection with activation of lipid oxidation, that significantly stimulated blood cells and caused alteration of vessel wall. In the persons studied there was significant decrease of the control of vessel wall over the increased cells aggregability. Conclusion.In comorbidity of arterial hypertension with dyslipidemia there is excessive erythrocyte, thrombocyte and neutrophils aggregation with a decrease of antiaggregation control by vessel wall. Russ

show abstract

Section: Discussionunclassified

Aggregation Properties of Blood Cells and Vascular Control Over Them in Patients With Arterial Hypertension and Dyslipidemia

Медведев¹,

Скорятина²

2015

Ross. kardiol. ž.

View full text Add to dashboard Cite

show abstract

“…58 Despite the negative findings of recent large-scale trials, several earlier studies -though at smaller scales -have reported an opposite finding. 18,33,[59][60][61][62][63][64] A recent meta-analysis also favored the benefits of niacin either as monotherapy or as an adjunct to statins in reducing CVD events. 64 It is also worth noting that both AIM-HIGH and HPS2-THRIVE studies were secondary prevention trials in subjects receiving optimal statin therapy.…”

Section: Discussionmentioning

confidence: 99%

Effect of niacin on endothelial function: A systematic review and meta-analysis of randomized controlled trials

Sahebkar

2014

Vasc Med

View full text Add to dashboard Cite

Endothelial dysfunction is an independent predictor of incident atherosclerotic cardiovascular disease (ACVD). Niacin possesses high-density lipoprotein (HDL)-elevating, antioxidant and anti-inflammatory properties, all potentially contributing to the amelioration of endothelial function. However, controversies exist among trials reporting the effects of niacin on endothelium-dependent flow-mediated dilation (FMD) as a reliable surrogate of endothelial function. The objective of this study was to assess the effect of niacin on brachial artery FMD using a meta-analysis of available evidence. MEDLINE and Scopus databases were searched for randomized controlled trials investigating the impact of niacin therapy on brachial artery FMD. Meta-analysis of eligible studies was conducted using a random-effects model. Pooled effects were measured by weighted mean difference (WMD) and 95% confidence intervals (CIs). Quality assessment, and subgroup, meta-regression and sensitivity analyses were conducted using standard methods. Among 596 citations, 19 full-text articles were read and seven were found to be eligible for inclusion. Eligible studies involved 441 subjects comprising 228 in the niacin and 213 in the control groups. Niacin therapy significantly improved FMD (WMD: 1.98%; 95% CI: 0.91-3.05%; p = 0.0003) and this effect was robust in the sensitivity analysis. The effect size was greater in the subgroup of studies administering higher doses of niacin (≥ 2000 mg/day) as well as those studies administering niacin for primary prevention of ACVD. Metaregression indicated no association between niacin-induced changes in FMD and changes in plasma HDL-cholesterol, lowdensity lipoprotein-cholesterol or triglycerides. None of the included studies could find any significant effect of niacin on nitroglycerin-mediated dilation. In conclusion, treatment with niacin improves endothelial function.

show abstract

“…The ARBITER 6-HALTS (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) trial showed that niacin not only favorably modified lipid profiles, but also reduced plaque formation in carotid and coronary arteries. 89 Unfortunately, the large outcome trial AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides), supported by the National Institutes of Health, was stopped after a little more than 3000 patients had been recruited, because of futility. 9 The trial has been criticized for its small sample size and the fact that the dose of simvastatin (which was used as background therapy to control LDL-C) had been adapted to the LDL levels achieved with either placebo or niacin.…”

Section: Hdl As a Therapeutic Targetmentioning

confidence: 99%

High-Density Lipoprotein

Lüscher

Landmesser

Eckardstein

et al. 2014

Circulation Research

235

View full text Add to dashboard Cite

show abstract

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

Abstract: Niacin induces regression of CIMT and is superior to ezetimibe for patients taking statins. (Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis; NCT00397657).

Cited by 207 publications

References 14 publications

Aggregation Properties of Blood Cells and Vascular Control Over Them in Patients With Arterial Hypertension and Dyslipidemia

Aggregation Properties of Blood Cells and Vascular Control Over Them in Patients With Arterial Hypertension and Dyslipidemia

Effect of niacin on endothelial function: A systematic review and meta-analysis of randomized controlled trials

High-Density Lipoprotein

Contact Info

Product

Resources

About